EVER Pharma Trials - LARVOL Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

minzasolmin (UCB0599) / UCB, Novartis

2020-003265-19: A 18-month study to evaluate the efficacy, safety, tolerability and pharmacokinetics of oral UCB0599 in study participants with early-stage Parkinson’s Disease

Not yet recruiting

450

Europe

UCB0599, UCB0599, Capsule, DaTSCAN

UCB Biopharma SRL, UCB Biopharma SRL

Early-stage Parkinson's disease, Early-stage Parkinson's disease, Diseases [C] - Nervous System Diseases [C10]

ORCHESTRA, NCT04658186 / 2020-003265-19: A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

Jul 2023 - Dec 2023 : Top-line data from P2 trial for participants with early Parkinson's disease

Completed

496

Europe, Canada, US

UCB0599, Placebo

UCB Biopharma SRL, The Parkinson Study Group

Early-stage Parkinson's Disease

09/24

NCT05543252: An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease

Terminated

428

Europe, Canada, US

Minzasolmin (UCB0599)

UCB Biopharma SRL

Parkinson's Disease

03/25

NCT05845645: A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharamacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B

Completed

UCB0599, Esomeprazole, Placebo, PBO

UCB Biopharma SRL

Healthy Study Participants

04/24

NCT06533475: A Study to Assess the Bioavailability of a New Tablet Formulation of Minzasolmin and the Effect of Food in Healthy Participants

Completed

Europe

Minzasolmin tablet formulation under fasting condition, UCB0599, Minzasolmin Granules in capsule under fasting condition, Minzasolmin tablet formulation under fed condition

UCB Biopharma SRL

Healthy Participants

11/24

Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma

NCT06208540: Clinical Characteristics and Treatment of Anosmia and Ageusia Due to SARS-CoV2 Variants

Completed

160

RoW

Cerebrolysin, Active arm, olfactory and gustatory trainings, controls

Sherifa Ahmed Hamed

Post-covid-19 Persistent Smell and Taste Disorders

04/24

05/24

MI22-00013, NCT06273020: Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke

Recruiting

RoW

Cerebrolysin, Brain-MRI with contrast after 10-14 days of cerebrolysin

Hospital Universitario Dr. Jose E. Gonzalez, Ever Neuro Pharma GmbH

Ischemic Stroke, Acute, Diabetes Mellitus, Type 2, Blood Brain Barrier

11/24

12/24

NCT04913831: Effects of Cerebrolysin on Level of Consciousness and Brain Metabolism in Disorder of Consciousness After Stroke: Single Center Randomized Controlled Study

Recruiting

RoW

Cerebrolysin, Placebo

Yonsei University

Stroke

03/24

CERBERUS, NCT06078215: CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke

Recruiting

350

Europe

Cerebrolysin, FPF (Fine Particle Fraction)-1070

Poznan University of Medical Sciences

Acute Ischemic Stroke

01/25

03/25

NCT06897176: Effects of Cerebrolysin on Language Ability in Non-fluent Aphasia Patients After Stroke: A Randomized, Placebo-controlled, Double-blinded, Single Center Study

Recruiting

RoW

Cerebrolyisin, Placebo

Yonsei University

Stroke

06/25

12/27

NCT04427241: Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness

Not yet recruiting

RoW

Cerebrolysin, Control

Konkuk University Medical Center, Ever Neuro Pharma GmbH

Disorder of Consciousness, Hemorrhagic Stroke

07/25

12/25

CLINCH, NCT06899464: Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point Trial

Not yet recruiting

14-day Cerebrolysin treatment, Standard of Care (SOC)

Cardinal Stefan Wyszynski University

Intracerebral Hemorrhage, Hemorrhagic Stroke, Intracerebral, Hemorrhagic Stroke, Stroke

01/27

04/27

2022-003382-38: Is Cerebrolysin efficient in neurorecovery after moderate-severe traumatic brain injury? Este Cerebrolysin eficient in neurorecuperare după traumatism cerebral moderat-sever?

Ongoing

440

Europe

Cerebrolysin, N07XXN3, Solution for injection/infusion, Cerebrolysin

FSNANO05012022, Fundatia pentru Studiul Nanoneurostiintelor si Neuroregenerarii

Moderate-severe traumatic brain injury Traumatism cerebral moderat-sever, Brain injury Traumatism cerebral, Diseases [C] - Nervous System Diseases [C10]

NCT04904341: Efficacy of Cerebrolysin Treatment as an add-on Therapy to Mechanical Thrombectomy in Acute Ischemic Stroke.

Recruiting

Europe

Cerebrolysin

Military Institute of Medicine, Poland, Brainomix Limited

Stroke, Ischemic, Stroke, Acute, Stroke Sequelae

12/23

12/24

NCT06052787: Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU

Recruiting

150

RoW

Cerebrolysin, amantadine sulfate, PK-MERZ

Ain Shams University

Traumatic Brain Injury

03/25

09/25

NCT05124353: Early Administration of Cerebrolysin on the Outcome of Patients With Acute Stroke Undergoing EVT

Recruiting

2/3

100

Europe

Cerebrolysin, neuroprotective treatment

Pomeranian Medical University Szczecin

Stroke, Acute, Ischemic

04/23

2019-001799-12: A clinical study on stimulating the brain to improve the function of a stroke-damaged arm Eine klinische Studie über die Stimulierung des Gehirns zur Funktionsverbesserung des durch einen Schlaganfall geschädigten Armes

Not yet recruiting

Europe

Cerebrolysin, Concentrate for solution for infusion, Cerebrolysin® - parenteral solution

EVER Neuro Pharma GmbH, EVER Neuro Pharma GmbH, VASCage GmbH

Subacute and chronic stroke, Medical condition several months after stroke, Diseases [C] - Nervous System Diseases [C10]

CERICA, NCT05755997: CERebrolysin in CADASIL

Active, not recruiting

RoW

Cerebrolysin, Renacenz, 0.9 % NaCl, Sodium Chloride

Ever Neuro Pharma GmbH, idv Datenanalyse & Versuchsplanung, XClinical GmbH

Cadasil

03/26

12/26

NCT05821075: Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy

Recruiting

1/2

RoW

Prednisolone, Cerebrolysin

October 6 University

Bell Palsy

10/24

12/24

NCT06339411: Exploring Cerebrolysin in Late Thrombectomy for Stroke: Blood-brain Barrier Biomarkers and Imaging Insights

Not yet recruiting

100

Cerebrolysin

Chang Gung Memorial Hospital

Acute Ischemic Stroke

12/26

07/27

NCT06489925: Cerebrolysin as an Add-On Therapy to Standard Treatment of Basilar Artery Occlusion

Not yet recruiting

Cerebrolysin, Cerebrolysin®

University Hospital "Sestre Milosrdnice", Ever Neuro Pharma GmbH

Basilar Artery Occlusion, Posterior Circulation Brain Infarction

05/25

05/26

NCT06429943: Cerebrolysin in SAH (Subarachnoidal Haemorrhage) - Observational Study

Completed

N/A

Europe

Pomeranian Medical University Szczecin

SAH (Subarachnoid Hemorrhage)

10/22

01/23

NCT05807503: Evaluation of the Effect of Neuroprotective Drug on Treatment Result in Patients After Traumatic Brain Injury

Completed

N/A

Europe

Cerebrolysin

Pomeranian Medical University Szczecin

TBI (Traumatic Brain Injury)

10/22

11/22

C-REGS2, NCT03480698: Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness

Completed

N/A

1851

Europe

Cerebrolysin

Ever Neuro Pharma GmbH, IDV Data analysis and study planning Dr. Rahlfs

Acute Ischemic Stroke

04/24

07/24

Cereb-POD, NCT05864677: Cerebrolysin in Prevention of Postoperative Delirium in Cardiac Surgery

Enrolling by invitation

N/A

100

Europe

Cerebrolysin

Medical University of Lublin

Neurocognitive Disorders, Surgery-Complications, Critical Illness, Brain Damage, Cardiac Disease

06/24

12/24

NCT06677502: Cerebrolysin in Critically Ill Patients With Delirium

Enrolling by invitation

N/A

500

Europe

Cerebrolysin, Saline Solution - IV

Medical University of Lublin

Cognitive Impairment

06/25

12/25

NCT06070753: A Prospective, Trial About Safety and Efficacy of Combined Treatment With Cerebrolysin in Acute Ischemic Hemispheric Stroke Patients Undergoing EndoVascular Treatment (EVT)

Recruiting

N/A

RoW

Cerebrolysin, Abrineurin

Shaare Zedek Medical Center

Acute Ischemic Stroke

06/24

12/24

NCT07043686: Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study

Recruiting

N/A

Europe

Cerebrolysin treatment, Standard treatment (including neurorehabilitation) of acute ischemic stroke

University Medical Centre Ljubljana

Ischemic Stroke, Acute, Rehabilitation Outcome, Cerebrolysin

07/27

10/27

NPT520-34 / EVER Pharma

No trials found

NPT1220-312 / EVER Pharma

No trials found

NPT1220-478 / EVER Pharma

No trials found

Cathepsin A inhibitor / EVER Pharma

No trials found

TLR2 antagonist / EVER Pharma

No trials found

NPT520-337 / EVER Pharma

No trials found

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

minzasolmin (UCB0599) / UCB, Novartis

2020-003265-19: A 18-month study to evaluate the efficacy, safety, tolerability and pharmacokinetics of oral UCB0599 in study participants with early-stage Parkinson’s Disease

Not yet recruiting

450

Europe

UCB0599, UCB0599, Capsule, DaTSCAN

UCB Biopharma SRL, UCB Biopharma SRL

Early-stage Parkinson's disease, Early-stage Parkinson's disease, Diseases [C] - Nervous System Diseases [C10]

Jul 2023 - Dec 2023 : Top-line data from P2 trial for participants with early Parkinson's disease

Completed

496

Europe, Canada, US

UCB0599, Placebo

UCB Biopharma SRL, The Parkinson Study Group

Early-stage Parkinson's Disease

09/24

NCT05543252: An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease

Terminated

428

Europe, Canada, US

Minzasolmin (UCB0599)

UCB Biopharma SRL

Parkinson's Disease

03/25

Completed

UCB0599, Esomeprazole, Placebo, PBO

UCB Biopharma SRL

Healthy Study Participants

04/24

NCT06533475: A Study to Assess the Bioavailability of a New Tablet Formulation of Minzasolmin and the Effect of Food in Healthy Participants

Completed

Europe

Minzasolmin tablet formulation under fasting condition, UCB0599, Minzasolmin Granules in capsule under fasting condition, Minzasolmin tablet formulation under fed condition

UCB Biopharma SRL

Healthy Participants

11/24

Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma

NCT06208540: Clinical Characteristics and Treatment of Anosmia and Ageusia Due to SARS-CoV2 Variants

Completed

160

RoW

Cerebrolysin, Active arm, olfactory and gustatory trainings, controls

Sherifa Ahmed Hamed

Post-covid-19 Persistent Smell and Taste Disorders

04/24

05/24

MI22-00013, NCT06273020: Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke

Recruiting

RoW

Cerebrolysin, Brain-MRI with contrast after 10-14 days of cerebrolysin

Hospital Universitario Dr. Jose E. Gonzalez, Ever Neuro Pharma GmbH

Ischemic Stroke, Acute, Diabetes Mellitus, Type 2, Blood Brain Barrier

11/24

12/24

NCT04913831: Effects of Cerebrolysin on Level of Consciousness and Brain Metabolism in Disorder of Consciousness After Stroke: Single Center Randomized Controlled Study

Recruiting

RoW

Cerebrolysin, Placebo

Yonsei University

Stroke

03/24

CERBERUS, NCT06078215: CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke

Recruiting

350

Europe

Cerebrolysin, FPF (Fine Particle Fraction)-1070

Poznan University of Medical Sciences

Acute Ischemic Stroke

01/25

03/25

NCT06897176: Effects of Cerebrolysin on Language Ability in Non-fluent Aphasia Patients After Stroke: A Randomized, Placebo-controlled, Double-blinded, Single Center Study

Recruiting

RoW

Cerebrolyisin, Placebo

Yonsei University

Stroke

06/25

12/27

NCT04427241: Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness

Not yet recruiting

RoW

Cerebrolysin, Control

Konkuk University Medical Center, Ever Neuro Pharma GmbH

Disorder of Consciousness, Hemorrhagic Stroke

07/25

12/25

CLINCH, NCT06899464: Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point Trial

Not yet recruiting

14-day Cerebrolysin treatment, Standard of Care (SOC)

Cardinal Stefan Wyszynski University

Intracerebral Hemorrhage, Hemorrhagic Stroke, Intracerebral, Hemorrhagic Stroke, Stroke

01/27

04/27

2022-003382-38: Is Cerebrolysin efficient in neurorecovery after moderate-severe traumatic brain injury? Este Cerebrolysin eficient in neurorecuperare după traumatism cerebral moderat-sever?

Ongoing

440

Europe

Cerebrolysin, N07XXN3, Solution for injection/infusion, Cerebrolysin

FSNANO05012022, Fundatia pentru Studiul Nanoneurostiintelor si Neuroregenerarii

Moderate-severe traumatic brain injury Traumatism cerebral moderat-sever, Brain injury Traumatism cerebral, Diseases [C] - Nervous System Diseases [C10]

NCT04904341: Efficacy of Cerebrolysin Treatment as an add-on Therapy to Mechanical Thrombectomy in Acute Ischemic Stroke.

Recruiting

Europe

Cerebrolysin

Military Institute of Medicine, Poland, Brainomix Limited

Stroke, Ischemic, Stroke, Acute, Stroke Sequelae

12/23

12/24

NCT06052787: Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU

Recruiting

150

RoW

Cerebrolysin, amantadine sulfate, PK-MERZ

Ain Shams University

Traumatic Brain Injury

03/25

09/25

NCT05124353: Early Administration of Cerebrolysin on the Outcome of Patients With Acute Stroke Undergoing EVT

Recruiting

2/3

100

Europe

Cerebrolysin, neuroprotective treatment

Pomeranian Medical University Szczecin

Stroke, Acute, Ischemic

04/23

Not yet recruiting

Europe

Cerebrolysin, Concentrate for solution for infusion, Cerebrolysin® - parenteral solution

EVER Neuro Pharma GmbH, EVER Neuro Pharma GmbH, VASCage GmbH

Subacute and chronic stroke, Medical condition several months after stroke, Diseases [C] - Nervous System Diseases [C10]

CERICA, NCT05755997: CERebrolysin in CADASIL

Active, not recruiting

RoW

Cerebrolysin, Renacenz, 0.9 % NaCl, Sodium Chloride

Ever Neuro Pharma GmbH, idv Datenanalyse & Versuchsplanung, XClinical GmbH

Cadasil

03/26

12/26

NCT05821075: Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy

Recruiting

1/2

RoW

Prednisolone, Cerebrolysin

October 6 University

Bell Palsy

10/24

12/24

NCT06339411: Exploring Cerebrolysin in Late Thrombectomy for Stroke: Blood-brain Barrier Biomarkers and Imaging Insights

Not yet recruiting

100

Cerebrolysin

Chang Gung Memorial Hospital

Acute Ischemic Stroke

12/26

07/27

NCT06489925: Cerebrolysin as an Add-On Therapy to Standard Treatment of Basilar Artery Occlusion

Not yet recruiting

Cerebrolysin, Cerebrolysin®

University Hospital "Sestre Milosrdnice", Ever Neuro Pharma GmbH

Basilar Artery Occlusion, Posterior Circulation Brain Infarction

05/25

05/26

NCT06429943: Cerebrolysin in SAH (Subarachnoidal Haemorrhage) - Observational Study

Completed

N/A

Europe

Pomeranian Medical University Szczecin

SAH (Subarachnoid Hemorrhage)

10/22

01/23

NCT05807503: Evaluation of the Effect of Neuroprotective Drug on Treatment Result in Patients After Traumatic Brain Injury

Completed

N/A

Europe

Cerebrolysin

Pomeranian Medical University Szczecin

TBI (Traumatic Brain Injury)

10/22

11/22

C-REGS2, NCT03480698: Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness

Completed

N/A

1851

Europe

Cerebrolysin

Ever Neuro Pharma GmbH, IDV Data analysis and study planning Dr. Rahlfs

Acute Ischemic Stroke

04/24

07/24

Cereb-POD, NCT05864677: Cerebrolysin in Prevention of Postoperative Delirium in Cardiac Surgery

Enrolling by invitation

N/A

100

Europe

Cerebrolysin

Medical University of Lublin

Neurocognitive Disorders, Surgery-Complications, Critical Illness, Brain Damage, Cardiac Disease

06/24

12/24

NCT06677502: Cerebrolysin in Critically Ill Patients With Delirium

Enrolling by invitation

N/A

500

Europe

Cerebrolysin, Saline Solution - IV

Medical University of Lublin

Cognitive Impairment

06/25

12/25

NCT06070753: A Prospective, Trial About Safety and Efficacy of Combined Treatment With Cerebrolysin in Acute Ischemic Hemispheric Stroke Patients Undergoing EndoVascular Treatment (EVT)

Recruiting

N/A

RoW

Cerebrolysin, Abrineurin

Shaare Zedek Medical Center

Acute Ischemic Stroke

06/24

12/24

NCT07043686: Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study

Recruiting

N/A

Europe

Cerebrolysin treatment, Standard treatment (including neurorehabilitation) of acute ischemic stroke

University Medical Centre Ljubljana

Ischemic Stroke, Acute, Rehabilitation Outcome, Cerebrolysin

07/27

10/27

NPT520-34 / EVER Pharma

No trials found

NPT1220-312 / EVER Pharma

No trials found

NPT1220-478 / EVER Pharma

No trials found

Cathepsin A inhibitor / EVER Pharma

No trials found

TLR2 antagonist / EVER Pharma

No trials found

NPT520-337 / EVER Pharma

No trials found



	Diseases Companies Products Productz Mechanisms of Action Sites